News for Newron Pharmaceuticals S.p.A. (NWRN.SW)

EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Half Year Results Newron presents H1 2024 results and provides busine...

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 17.06.2024 / 10:14...

Ad hoc announcement pursuant to Art. 53 LR Further study analysis reveals significant multi-domain benefits in PANSS and Clinical Global Impression of Change ratings Benefit on efficacy measures...

EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Annual Report Newron presents 2023 financial results and provides 202...

EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Financing Newron announces agreement with the European Investment Ban...

EQS-News: Newron Pharmaceuticals S.p.A. / Key word: Financing  Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to...

EQS-News: Newron Pharmaceuticals S.p.A. / Key word: Conference/Study results Newron presents exciting new data from study 014/015 at CINP World Congress of Neuropsychopharmacology and... | May 15, 2023

Further data from study 014/015 of evenamide in treatment-resistant schizophrenia confirms potentially relevant role of glutamatergic release modification when added to TRS patients not responding... | May 3, 2023

Results from all 161 patients at the 6-week primary endpoint show a statistically significant improvement over baseline in all efficacy measures Results consistent with interim data from first 100... | March 20, 2023

EQS-News: Newron Pharmaceuticals S.p.A. / Key word: Study results Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating... | March 20, 2023

Read Entasis Therapeutics (NASDAQ:ETTX) and Newron Pharmaceuticals (OTCMKTS:NWPHF) Head-To-Head Analysis at ETF Daily News

EQS Group-Ad-hoc: Newron Pharmaceuticals SpA / Key word: Personnel Change in Newron Board of Directors 01-Dec-2021 / 17:46 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The... | December 1, 2021

EQS Group-Ad-hoc: Newron Pharmaceuticals SpA / Key word: Half Year Results Newron announces Half-Year 2021 results 16-Sep-2021 / 07:01 CET/CEST Release of an ad hoc announcement pursuant to Art. 53... | September 16, 2021

EQS Group-Ad-hoc: Newron Pharmaceuticals SpA / Key word: Study Newron Initiates First Potentially Pivotal Study with Evenamide in Patients with Schizophrenia 06-Sep-2021 / 07:01 CET/CEST Release of... | September 6, 2021